Shannon Parisotto Sells 2,039 Shares of Charles River Laboratories International (NYSE:CRL) Stock

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Shannon Parisotto sold 2,039 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $294.12, for a total transaction of $599,710.68. Following the completion of the transaction, the executive vice president directly owned 4,807 shares of the company’s stock, valued at approximately $1,413,834.84. This trade represents a 29.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Stock Up 1.3%

Charles River Laboratories International stock opened at $295.23 on Friday. The firm has a 50 day simple moving average of $234.99 and a 200 day simple moving average of $193.86. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. Charles River Laboratories International, Inc. has a 1-year low of $144.26 and a 1-year high of $299.32. The firm has a market capitalization of $14.09 billion, a price-to-earnings ratio of -60.87, a P/E/G ratio of 3.02 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. During the same quarter in the prior year, the business posted $3.12 earnings per share. The business’s quarterly revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, analysts predict that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CRL has been the subject of a number of recent analyst reports. Piper Sandler set a $300.00 target price on Charles River Laboratories International in a report on Monday, August 10th. CLSA downgraded shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target on the stock. in a report on Monday, July 20th. Royal Bank Of Canada raised their price objective on shares of Charles River Laboratories International from $215.00 to $282.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. Weiss Ratings raised shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 1st. Finally, Robert W. Baird set a $291.00 target price on shares of Charles River Laboratories International in a report on Thursday, August 6th. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $255.65.

More Charles River Laboratories International News

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Charles River is collaborating with Medigen Vaccine Biologics to advance vaccine-development programs using next-generation sequencing. The partnership could expand CRL’s support for biologics and vaccine customers, although financial terms were not disclosed. Charles River Labs and Medigen Vaccine collaboration
• Positive Sentiment: Analysts highlight DSA’s return to organic growth, stronger bookings, and new testing capabilities as key drivers behind CRL’s approximately 88.6% one-year advance. These trends support the company’s strategy of broadening its role in drug-development services. Charles River rally drivers
• Neutral Sentiment: Options-market activity suggests traders are positioning for a potentially significant move in CRL shares, but the activity does not establish whether the anticipated move will be upward or downward. CRL options activity
• Negative Sentiment: Zacks cautions that the recent 33.3% monthly surge has raised the bar for execution. Margin pressure and a premium valuation may constrain upside unless bookings and guidance continue to improve. CRL valuation and rally outlook
• Negative Sentiment: Director Nancy Andrews sold 573 shares for approximately $163,443, reducing her direct holdings by 28.5%. The transaction is modest but adds to investor focus on insider selling after the stock’s rally. Nancy Andrews insider sale
• Negative Sentiment: EVP Shannon M. Parisotto sold 2,039 shares for approximately $599,711, reducing direct ownership by 29.8%; the sale was made under a pre-arranged Rule 10b5-1 trading plan, which lessens its signaling value. Shannon Parisotto insider sale

Institutional Trading of Charles River Laboratories International

Hedge funds have recently made changes to their positions in the stock. Continuum Advisory LLC purchased a new stake in Charles River Laboratories International during the second quarter valued at about $30,000. Los Angeles Capital Management LLC bought a new position in Charles River Laboratories International during the fourth quarter valued at approximately $42,000. Sfam LLC purchased a new position in shares of Charles River Laboratories International during the fourth quarter worth approximately $43,000. Activest Wealth Management raised its stake in shares of Charles River Laboratories International by 10,900.0% during the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after acquiring an additional 218 shares in the last quarter. Finally, Elyxium Wealth LLC bought a new stake in shares of Charles River Laboratories International in the 4th quarter worth approximately $46,000. 98.91% of the stock is owned by institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.